#Galectin Therapeutics Inc

[third-new]

The chief medical officer of Galectin Therapeutics sold $12,044 worth of shares by Investing.com

Jamil Khurram, Chief Medical (TASE:) This officer Galectin Therapeutics, Inc. (NASDAQ:), recently sold 13,654 shares of the company's common stock. Shares traded at an average price of $0.8821, or about $12,044. This transaction was made under the 10b5-1 trading plan described earlier. The sale comes amid a challenging period for GALT, with the stock down about 58% in the past week. According to…

[newtras]

The chief medical officer of Galectin Therapeutics sold $12,044 worth of shares by Investing.com

Jamil Khurram, Chief Medical (TASE:) This officer Galectin Therapeutics, Inc. (NASDAQ:), recently sold 13,654 shares of the company's common stock. Shares traded at an average price of $0.8821, or about $12,044. This transaction was made under the 10b5-1 trading plan described earlier. The sale comes amid a challenging period for GALT, with the stock down about 58% in the past week. According to…

[newbizz]

The chief medical officer of Galectin Therapeutics sold $12,044 worth of shares by Investing.com

Jamil Khurram, Chief Medical (TASE:) This officer Galectin Therapeutics, Inc. (NASDAQ:), recently sold 13,654 shares of the company's common stock. Shares traded at an average price of $0.8821, or about $12,044. This transaction was made under the 10b5-1 trading plan described earlier. The sale comes amid a challenging period for GALT, with the stock down about 58% in the past week. According to…

[satrthere]

The chief medical officer of Galectin Therapeutics sold $12,044 worth of shares by Investing.com

Jamil Khurram, Chief Medical (TASE:) This officer Galectin Therapeutics, Inc. (NASDAQ:), recently sold 13,654 shares of the company's common stock. Shares traded at an average price of $0.8821, or about $12,044. This transaction was made under the 10b5-1 trading plan described earlier. The sale comes amid a challenging period for GALT, with the stock down about 58% in the past week. According to…

[colinwilson11]

Treatment Of Liver Cirrhosis Market To Grow At Highest Pace Due To Rising Alcohol Intake

Liver cirrhosis refers to scarring (fibrosis) of the liver tissue and poor functioning of the liver. It is caused by excessive alcohol consumption over many years or due to chronic hepatitis virus infections such as hepatitis B or C. The progression of fibrosis leads to nodule formation and ultimately to cirrhosis. The key symptoms of liver cirrhosis include jaundice, fatigue, abdominal pain, weakness, loss of appetite, nausea and vomiting. Treatment for liver cirrhosis depends on the severity of the disease and includes medications to improve liver functions, antibiotics to treat infections, diuretics to remove excess fluid and sometimes orthotopic liver transplantation.

The Liver Cirrhosis Market is estimated to be valued at US$ 1.41 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the liver cirrhosis market are Madrigal Pharmaceuticals, Inc., Galectin Therapeutics Inc., Grifols Therapeutics LLC, Cyma Bay Therapeutics, Akero Therapeutics, Inc.

Key players operating in the liver cirrhosis market are increasingly investing in R&D to develop advanced treatment options. For instance, Madrigal Pharmaceuticals is developing resmetirom, a first-in-class thyroid hormone receptor beta-selective agonist for the treatment of non-alcoholic steatohepatitis (NASH) and liver cirrhosis.

The growing prevalence of excessive alcohol consumption and obesity are major factors fueling the demand for liver cirrhosis treatment solutions. According to WHO, around 3 million deaths each year result from harmful use of alcohol. Excessive alcohol intake damages liver cells making the organ less able to regenerate, leading to the development of cirrhosis over the years.

Technological advancements in liver transplantation techniques coupled with the emergence of effective post-transplant medications have increased the eligibility of patients and survival rates post transplantation. Shortage of liver donors however remains a key challenge. Companies are investing in development of artificial or bio-engineered livers as potential alternatives.

Market Trends

Increasing Adoption Of Targeted Therapies: Pharma companies are focusing on developing targeted therapies for liver cirrhosis that specifically act on certain molecular targets or pathways involved in disease progression. For example, Galectin Therapeutics' drug belapectin blocks galectin-3 activity involved in fibrotic response and necrosis.

Rise Of Combination Therapies: Due to multifactorial nature of the disease, companies are exploring efficacy of combining two or more treatment modalities for synergistic effects. For example, combination of antiviral medications with immunomodulators to achieve sustained virologic response.

Market Opportunities

Asia Pacific presents high growth prospects owing to changing lifestyles, abusive consumption of alcohol and growing obesity rates. Public-private partnerships can help facilitate more affordable healthcare access in emerging economies.

Emergence of non-invasive diagnostic tools leveraging imaging and biomarkers hold potential to precisely diagnose and monitor disease progression and treatment response without need for repeated liver biopsies. This can increase patient acceptance and compliance.

Impact Of COVID-19 On Liver Cirrhosis Market Growth

The COVID-19 pandemic has significantly impacted the growth of the liver cirrhosis market. During the initial phases of the pandemic, factors like lockdowns, restrictions on non-essential medical services led to postponement of diagnosis procedures and delay in treatment. This adversely impacted the market growth initially. However, as the healthcare sector learned to cope and adapt to the new normal, telehealth services gained prominence helping maintain continuity of care virtually. With the development and availability of vaccines as well, the market is recovering fast. However, challenges like availability of medical staff, hospital beds, and potential risks of severe COVID infection in cirrhosis patients still persist and need to be addressed. The immediate focus post pandemic is to boost diagnosis and treatment rates back to pre-COVID levels. Intensifying awareness campaigns and policies promoting community healthcare can aid in early detection and management of cirrhosis cases.

Geographical Regions With Highest Liver Cirrhosis Market Value

North America dominates the Liver Cirrhosis Market in terms of value. The region accounted for over 35% market share in 2024 owing to rising prevalence of cirrhosis caused by non-alcoholic steatohepatitis (NASH) and alcohol abuse. Growing healthcare spending and availability of advanced treatment options have further augmented the regional market. Europe ranks second with major markets being Germany, United Kingdom, France and Italy. Developed healthcare infrastructure, supportive reimbursement environment and presence of key industry players have boosted the European market.

Fastest Growing Region For Liver Cirrhosis Market

Asia Pacific is identified as the fastest growing regional market for liver cirrhosis expected to expand at a CAGR of around 7% during the forecast years. Growing consumption of alcohol, rising obesity rates attributed to changing lifestyles and dietary habits have majorly contributed to increased cirrhosis burden in the region. Countries like China, India and Japan have emerged as high potential markets. Rapid economic development, rising healthcare expenditure, growing medical tourism are some factors favoring the Asia Pacific liver cirrhosis market. Initiatives to spread awareness about lifestyle-related liver diseases can further augment the regional market opportunities.

Get more insights on this topic: https://www.trendingwebwire.com/liver-cirrhosis-market-poised-for-growth-amid-rising-adoption-of-targeted-therapies/

Author Bio:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. (LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

What Are The Key Data Covered In This Liver Cirrhosis Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Liver Cirrhosis Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Liver Cirrhosis Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Liver Cirrhosis Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Liver Cirrhosis Market vendors

FAQ’s

Q.1 What are the main factors influencing the Liver Cirrhosis Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Liver Cirrhosis Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Liver Cirrhosis Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[fmarkets]

Galectin Therapeutics Inc Reports Strong First Quarter 2024 Financial Results2. $GALT #Nasdaq

Management's Focus on Research Operations Drives Positive Business Update Date: May 15, 2024 Galectin Therapeutics, Inc. (NASDAQ: GALT), a leading developer of therapeutics targeting galectin proteins, recently announced its financial results and provided a business update for the quarter ended March 31, 2024. During the earnings season from January to March 2024, investors did not anticipate any significant changes in the company's revenue. However, there was close scrutiny of GALT's operating loss, which amounted to $9.648 million during the s

[reportwire]

Research Analysts’ Updated EPS Estimates for February, 26th (APPF, BKH, CIR, CSLT, DLTH, GALT, LOV, OPY, ORN, SRNE)

Research Analysts’ Updated EPS Estimates for February, 26th (APPF, BKH, CIR, CSLT, DLTH, GALT, LOV, OPY, ORN, SRNE)

Research Analysts’ updated eps estimates for Saturday, February 26th: AppFolio (NASDAQ:APPF) was upgraded by analysts at StockNews.com from a sell rating to a hold rating. Black Hills (NYSE:BKH) was upgraded by analysts at StockNews.com from a sell rating to a hold rating. CIRCOR International (NYSE:CIR) was upgraded by analysts at StockNews.com from a hold rating to a buy rating. StockNews.com…

[ustribunenews-blog]

(Nasdaq:GALT) Galectin Therapeutics Inc Sets 52 Week High Record

(Nasdaq:GALT) Galectin Therapeutics Inc Sets 52 Week High Record

Galectin Therapeutics Inc (Nasdaq:GALT)

June 18th, 2018

Galectin Therapeutics Inc closed Monday up 4.69%, a $0.41 increase to close on $9.16. In addition it hit a new 52 week high of $9.49. The stock continues to trade well at 616% of its 52 week low of $1.28. In addition to finishing higher, trading volumes were solid at 342% of normal which can indicate investors see opportunities. Be aware…

[snehalaxel]

Galectin 3 Market Growth By Top Companies with Forecast 2027

"

Galectin 3 Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report:https://axelreports.com/request-sample/53313

A 360 degree outline of the competitive scenario of the Global Galectin 3 Market is presented by Axel Reports Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the market’s future growth, wide-ranging analysis of these extensions on the market’s future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Reasons for buying this report:

It offers an analysis of changing competitive scenario.

For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.

It offers seven-year assessment of Global Galectin 3

It helps in understanding the major key product segments.

Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.

It offers regional analysis of Global Galectin 3 Market along with business profiles of several stakeholders.

It offers massive data about trending factors that will influence the progress of the Global Galectin 3

Get ToC for the overview of the premium report @ https://axelreports.com/industry-analysis/2021-2027-global-and-regional-galectin-3/53313

By Market Players: Angion Biomedica Corp GlycoMimetics Inc Bristol-Myers Squibb Company Galectin Therapeutics Inc MandalMed Inc iTeos Therapeutics SA By Type GAL-300 GRMD-03 ANG-4021 KTI Others By Application Liver Cirrhosis Portal Hypertension Metastatic Melanoma Others

A detailed outline of the Global Galectin 3 Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Galectin 3 Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Galectin 3 Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Galectin 3 Market. The feasibility of the new report is also measured in this research report.

Make an Enquiry for purchasing this Report :https://axelreports.com/enquiry-before-buying/53313

Table of Contents:

Global Galectin 3 Market Overview

Economic Impact on Industry

Market Competition by Manufacturers

Production, Revenue (Value) by Region

Production, Revenue (Value), Price Trend by Type

Market Analysis by Application

Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Global Galectin 3 Market Forecast

ABOUT US:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact: Axel Reports Akansha G (Knowledge Partner) Office No- B 201 Pune, Maharashtra 411060 Phone: US +18488639402 Email: sales@axelreports.com/ Web: https://axelreports.com/

"

[covidimpact]

Galectin Inhibitor Therapeutics Market Size, In-depth Analysis Report and Global Forecast to 2027

Galectin Inhibitor Therapeutics Market report published by Value Market Research delivers a comprehensive market analysis covering of market size, share, value, growth and trends for the forecast period of 2021-2027. The report includes data regarding market attractiveness analysis by segments, company share analysis and recent developments by key players. Moreover, this market report also covers regional and country market analysis in detail.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the galectin inhibitor therapeutics market include Galectin Therapeutics Inc, MandalMed, Inc, G3 Pharmaceuticals, Angion, iTeos, GlycoMimetics, and Galecto Biotech among others.S. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Get more information on "Global Galectin Inhibitor Therapeutics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/galectin-inhibitor-therapeutics-market/download-sample

Market Dynamics

The great potential of galectin inhibitor therapeutics in cancer treatment, fibrosis, and cardiovascular diseases is the primary stimulant anticipated to drive this market’s growth. The attractive therapeutic opportunity offered by these anti-migratory, anti-invasive, and anti-angiogenic galectin inhibitors in treating several chronic diseases will further propel market growth. The emergence of galectin protein as a significant focus of research and pharmaceutical development for a wide range of medical conditions will boost the market growth. This market’s critical challenges are the complexities of developing effective therapeutics and the delivery of intact galectin to the desired site. The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give inclusive assessment of each segment in the global market of galectin inhibitor therapeutics.

Browse Global Galectin Inhibitor Therapeutics Market Research Report with detailed TOC at https://www.valuemarketresearch.com/report/galectin-inhibitor-therapeutics-market

Market Segmentation

This section of the galectin inhibitor therapeutics market report  provides detailed data on the segments by analyzing them grographically, thereby assisting the strategist in identifying the target demographics for the respective product or service. By Indication 

Fibrosis

Cancer     immunotherapy

Dermatology

Others

By Route of Aministration

Oral

Parenteral

Others

By End-Users

Hospitals

Homecare

Specialty     Clinics

Others

By Distribution Channel

hospital     pharmacy

online     pharmacy

retail     pharmacy

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for aerosol valve market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

Purchase Complete Global Galectin Inhibitor Therapeutics Market Research Report at https://www.valuemarketresearch.com/contact/galectin-inhibitor-therapeutics-market/buy-now

About Us:

Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information.

We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.

Contact:

Value Market Research

401/402, TFM, Nagras Road, Aundh, Pune-7.

Maharashtra, INDIA.

Tel: +1-888-294-1147

Email: sales@valuemarketresearch.com

Website:

https://www.valuemarketresearch.com

[ustribunenews-blog]

Setting 52 Week High, Galectin Therapeutics Inc (Nasdaq:GALT) Finishes At $8.75

Setting 52 Week High, Galectin Therapeutics Inc (Nasdaq:GALT) Finishes At $8.75

Galectin Therapeutics Inc (Nasdaq:GALT)

June 15th, 2018

Amidst falling markets Galectin Therapeutics Inc closed Friday up 7.23%, a $0.59 increase to close on $8.75. In addition it hit a new 52 week high of $8.79. The stock continues to trade well at 584% of its 52 week low of $1.28. Galectin Therapeutics Inc bounced 14.16% between low and high. In addition to finishing higher, trading volumes…

[medicalnewstoday]

Kidney Fibrosis Treatment Market Trending Scenario, Advance Analysis and Forecast to 2020

Fibrosis refers to a phenomenon of development of excessive connective tissue as a result of some injury or some disease. It results in formation of a layer around an organ in a repetitive manner which results in improper working of that organ. It often leads to scarring. Fibrosis occurs in various organs and is named according to its location. For instance, fibrosis in lungs is known as pulmonary fibrosis, whereas, fibrosis in liver is known as cirrhosis. Kidney fibrosis may be caused due to disease in kidney. It may be any stage from chronic kidney disease (CKD) to end-stage renal disease (ESRD). In this condition, kidneys stop working and gradually require transplantation. Various medications that are available in the market for treatment of kidney fibrosis are Renin inhibitors, Vasopeptidase inhibitors, Angiotensin II receptor blockers (ARBs), Angiotensin-converting enzyme (ACE) inhibitors and Pirfenidones. Increasing prevalence of kidney diseases and no other alternative treatment available is driving the market for kidney fibrosis treatment.

North America, followed by the Europe, dominates the global market for kidney fibrosis due to large number of aging population and better healthcare facilities available in the region. In addition, there is high prevalence of kidney diseases in the region. According to The Centers for Disease Control and Prevention (CDC), a public health institute in 2014, in the U.S., it is estimated that more than 20 million people are suffering from chronic kidney disease. Asia is expected to show high growth rate in the next few years in global kidney fibrosis treatment market.

For detailed insights on enhancing your product footprint, request for a Sample here @ https://www.persistencemarketresearch.com/samples/3102

China and India are expected to be the fastest kidney fibrosis market in Asia region. Some of the key driving forces for kidney fibrosis market in emerging countries are increasing R&D investment, large pool of patients, rising government funding and growing level of awareness.

Diseases such as obesity accelerate the incidence of kidney fibrosis. In addition, habits such smoking also adds to increment in incidence of kidney fibrosis. Increasing patient pool, rising awareness about treatment of kidney diseases and government funding are some of the key factors driving the kidney fibrosis market. In addition, introduction of safer and effective therapeutics for the treatment of kidney fibrosis is driving the market. However, high cost involved and no success for all the cases is restraining the kidney fibrosis market.

Introduction of the concept of personalized medicines, mono-therapeutic approaches or combination of therapies are expected to offer good opportunities for kidney fibrosis market. In addition, introduction statins for, which are related to lowering of lipid content, thus expected to be an efficient treatment for kidney scarring. Growing demographics and economies in the developing countries such as India and China in Asia and other countries in South East Asia, Latin America and Middle East are expected to offer high growth in kidney fibrosis treatment market.

To receive extensive list of important regions, ask for TOC here @ https://www.persistencemarketresearch.com/toc/3102

One of the major trends that have been observed in kidney fibrosis treatment market includes various pharmaceutical and biotechnology companies involved in R&D of some novel medications for the treatment of kidney fibrosis. Some of the key companies dealing in kidney fibrosis treatment market are

Hoffmann-La Roche Ltd.

Pfizer

La Jolla Pharmaceutical Company

Merck & Co.

InterMune

Galectin Therapeutics

Other companies dealing the kidney fibrosis treatment market which have significant presence are

ProMetic Life Sciences Inc.

BioLineRx

Genzyme Corporation

[letsmarketingworld-blog]

Plaque Psoriasis Market Share and Growth Opportunity: Type, major Companies and more

Global Plaque Psoriasis Market is expected to register a steady CAGR of 4.03% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017.

Plaque psoriasis is a type of skin disorder wherein patients suffer from large dry, itchy patches of skin on their bodies. These patches constitute of skin-cell build up and are generally prevalent on the scalp, elbows, lower back and knees. This condition is the most common variant of psoriasis which is an autoimmune chronic disorder. Although, no commercialized treatment methods are available, various disease management therapies are being commercialized in the market.

Key Market Competitors:

Few of the major competitors currently working in the global plaque psoriasis market are Johnson & Johnson Services, Inc.; AbbVie Inc.; Amgen Inc.; Novartis AG; Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.; Sun Pharmaceutical Industries Ltd.; LEO Pharma; CELGENE CORPORATION; Can Fite Biopharma; UCB S.A.; ALLERGAN; Dermira, Inc.; Galectin Therapeutics Inc.; Biogen; Dr. Reddy’s Laboratories Ltd.; Bausch Health; LUPIN and AstraZeneca among others.

Get | Exclusive Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-plaque-psoriasis-market

Plaque Psoriasis market report brings together a detailed study of the present and upcoming opportunities to elucidate the future investment in the Pharmaceutical industry. This report is a valuable source of assistance for companies and individuals that offers industry chain structure, business strategies and proposals for new project investments. Plaque Psoriasis report introduces top to bottom evaluation of the Pharmaceutical industry including empowering technologies, key trends, market drivers, challenges, standardization, regulatory landscape, opportunities, future guide, value chain, ecosystem player profiles and strategies. The report also analyses various inhibitors as well as motivators of the market in both quantitative and qualitative manners to provide accurate information to the end users.

Market Drivers

Increasing costs incurred on biologic therapeutics for the treatment of various disorders from the U.S. region is expected to drive the growth of the market

Availability of easy to utilize therapeutic systems such as phototherapy and topical therapeutic system for the disease are factors driving the growth of the market

Lack in the availability of therapies for treating the disease is expected to induce greater innovations and advancements in the market

Market Restraints

Lack of effectiveness in the treatment of the disease through topical therapy system is expected to restrict the growth of the market

High costs associated with the biologic therapy systems for the disease is also expected to restrict the growth of the market

Lack of effective reimbursement scenarios for the treatment of the disease; this factor is also expected to restrain the growth of the market

Competitive Analysis:

Global plaque psoriasis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of plaque psoriasis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Segmentation: Plaque Psoriasis Market

By Therapy Type (Topical, Phototherapy, Systemic Agents, Biologic Therapies)

By Application (Hospitals, Clinics, Others)

By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Reasons to Purchase this Report

Current and future of global anesthesia monitoring market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Browse full report @ https://www.databridgemarketresearch.com/reports/global-plaque-psoriasis-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Related Reports:

Global Genomics Market

Global Human Embryonic Stem Cell Market

[wesagar1994]

Plaque Psoriasis Market Analysis, Trends and Future Outlook, Size, Strategies and Forecasts

Global Plaque Psoriasis Market is expected to register a steady CAGR of 4.03% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017.

Key Market Competitors:

Few of the major competitors currently working in the global plaque psoriasis market are Johnson & Johnson Services, Inc.; AbbVie Inc.; Amgen Inc.; Novartis AG; Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.; Sun Pharmaceutical Industries Ltd.; LEO Pharma; CELGENE CORPORATION; Can Fite Biopharma; UCB S.A.; ALLERGAN; Dermira, Inc.; Galectin Therapeutics Inc.; Biogen; Dr. Reddy’s Laboratories Ltd.; Bausch Health; LUPIN and AstraZeneca among others.

Get | Exclusive Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-plaque-psoriasis-market

Market Drivers

Increasing costs incurred on biologic therapeutics for the treatment of various disorders from the U.S. region is expected to drive the growth of the market

Availability of easy to utilize therapeutic systems such as phototherapy and topical therapeutic system for the disease are factors driving the growth of the market

Lack in the availability of therapies for treating the disease is expected to induce greater innovations and advancements in the market

Market Restraints

Lack of effectiveness in the treatment of the disease through topical therapy system is expected to restrict the growth of the market

High costs associated with the biologic therapy systems for the disease is also expected to restrict the growth of the market

Lack of effective reimbursement scenarios for the treatment of the disease; this factor is also expected to restrain the growth of the market

Competitive Analysis:

Global plaque psoriasis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of plaque psoriasis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry about Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-plaque-psoriasis-market

Segmentation: Plaque Psoriasis Market

By Therapy Type (Topical, Phototherapy, Systemic Agents, Biologic Therapies)

By Application (Hospitals, Clinics, Others)

By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Reasons to Purchase this Report

Current and future of global anesthesia monitoring market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Browse full report @ https://www.databridgemarketresearch.com/reports/global-plaque-psoriasis-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Related Reports:

Global Genomics Market

Global Human Embryonic Stem Cell Market

[yervand63]

The Galectin Signature - Galectin Therapeutics, Inc. (NASDAQ:GALT)

The Galectin Signature – Galectin Therapeutics, Inc. (NASDAQ:GALT)

Introduction

In a previous blog post,GR-MD-02: Keytruda’s Partner, I outlined the rationale and mechanisms for galectin-3 blockade using Galectin Therapeutics’ (GALT) GR-MD-02 to improve clinical results of checkpoint inhibitor (anti-PD-1) therapy. There have been two highly significant developments in this field of interest to investors.

Significant Developments: I/O

Firstly, at a recent…

[scienceblogtumbler]

Novel Antisense Drug Shows Promise in Slowing Fatty Liver Disease

Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San Diego School of Medicine reports that inhibition of a key enzyme safely and effectively improved the health of persons with non-alcoholic fatty liver disease (NAFLD), a chronic metabolic disorder that affects hundreds of millions of people worldwide.

The gene silencing approach represents a novel way to reverse NAFLD. The findings are published in the June 15, 2020 online issue of The Lancet Gastroenterology and Hepatology.

NAFLD occurs when fat accumulates in liver cells due to causes other than excessive alcohol intake. The precise cause is not known, but diet and genetics are believed to play substantial roles. The condition is typically not noticed until the disease is well-advanced, and perhaps has transitioned to non-alcoholic steatohepatitis (NASH), a progressive form that can lead to cirrhosis, liver cancer and liver failure.

There is no cure. Treatment primarily consists of ameliorating contributory factors, such as losing weight, improving diet, exercising more and controlling for other conditions, such as diabetes and hypertension. No Food and Drug Administration-approved medications exist. In worst cases, a liver transplant may be required.

“NAFLD wasn’t even recognized as a disease three decades ago; now it is alarmingly prevalent, affecting roughly one-quarter of all Americans and emerging as one of the leading causes for liver transplant in the United States,” said the study’s lead author Rohit Loomba, MD, professor of medicine in the Division of Gastroenterology at UC San Diego School of Medicine and director of the UC San Diego NAFLD Research Center. “Given its relative ubiquity and its potentially calamitous consequences, safe and effective treatments are absolutely needed.”

In the double-blind, randomized, placebo-controlled Phase II trial, Loomba and colleagues enrolled 44 qualifying participants at 16 sites in Canada, Poland and Hungary. For 13 weeks, participants were injected with either an antisense inhibitor called IONIS-DGAT2 or a placebo. The inhibitor, produced by Carlsbad-based Ionis Pharmaceuticals, interferes with Diacylglycerol-O-acyltransferace or DGAT2, one of two enzyme forms required to catalyze or accelerate the production of triglycerides, a type of fat found in blood. High levels of triglycerides boost fat storage throughout the body, including the liver.

The researchers found that after 13 weeks of treatment, participants who received the enzyme inhibitor experienced measurable reductions in fatty liver levels compared to baseline, without elevated levels of fats, enzymes or sugars in the blood. There were six reported serious adverse events, including a cardiac arrest and deep vein thrombosis, but the researchers determined the events were unrelated to the study drug.

“These findings showed robust reduction in liver fat by MRI without corresponding increases in blood lipids,” said Loomba. “Given significant proportion of patients achieving roughly a 30 percent reduction in MRI-PDFF, the threshold that corresponds with higher odds of histologic response when treated for a longer duration, it looks like after just 13 weeks of treatment, the drug was actually slowing progression of NAFLD to NASH.

“All of this is very encouraging and argues for the next step: longer term trials to further investigate the potential of this drug in improvement of liver histologic features associated with NASH, the progressive sub-type of NAFLD.”

Co-authors of the study include: Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A. Hannan, Richard S. Geary, Brenda F. Baker and Sanjay Bhanot, all at Ionis Pharmaceutical, Carlsbad, Calif.

Funding for this research came from Ionis Pharmaceuticals. Loomba is supported, in part, by the National Institute of Diabetes and Digestive and Kidney Diseases (grants R01DK106419 and P30DK120515).

Disclosures: Rohit Loomba is a consultant or advisory board member for Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirius, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Intercept, Ionis, Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus, and Siemens. He is also co-founder of Liponexus, Inc. His co-authors are all employees and/or stockholders of Ionis Pharmaceuticals.

source https://scienceblog.com/516943/novel-antisense-drug-shows-promise-in-slowing-fatty-liver-disease/